Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 6Recruiting 5Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Metastatic Castration-resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 35Androgen Antagonists 34Radiosurgery 32Radiotherapy 31Prednisone 26darolutamide 24Abiraterone Acetate 24Leuprolide 22Docetaxel 22apalutamide 20Pluvicto 19abiraterone 18Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12pembrolizumab 11X-Rays 11Surveys and Questionnaires 11luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × testosterone 17 beta-cypionate × Clear all
NCT06305598 2026-05-15

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1 Recruiting
14 enrolled
Genitourinary

Prostatic Neoplasms

NCT07142551 2026-03-11

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

University of Washington

Phase 2 Recruiting
69 enrolled
Genitourinary

Prostatic Neoplasms

NCT06059118 2026-01-14

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡